Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone

Peer Review reports

Original Submission
29 Oct 2021	Submitted	Original manuscript
20 Apr 2022	Reviewed	Reviewer Report - Alexander Gough
27 Jun 2022	Reviewed	Reviewer Report - Molly Jeffery
19 Jul 2022	Author responded	Author comments - John Marsden
Resubmission - Version 2
19 Jul 2022	Submitted	Manuscript version 2
22 Jul 2022	Reviewed	Reviewer Report - Molly Jeffery
23 Jul 2022	Reviewed	Reviewer Report - Alexander Gough
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
25 Jul 2022	Editorially accepted
19 Aug 2022	Article published	10.1186/s13063-022-06595-0

Back to article page